论文部分内容阅读
在过去的5年中,中国OTC市场的年增长率超过20%,其市场规模和增长潜力都非常诱人。近期,OTC领域竞争本就异常激烈的胃药和感冒市场又有两支新军加入:全球排名第五、中国市场处方药销售雄踞跨国药企之首的阿斯利康,借洛赛克转为OTC之机强势出击;成立于1943年、国内原料药巨头新华制药以雷霆之势继续推广感冒药爱菲乐。由此使国内OTC市场更显欣欣向荣之景。
Over the past five years, the annual growth rate of China’s OTC market has exceeded 20%, and its market size and growth potential are very attractive. Recently, there have been two new forces joining the fiercely competitive stomach and cold market in the OTC field: the fifth largest in the world, AstraZeneca, which tops the list of leading pharmaceutical companies in the Chinese market, OTC machine strong attack; was established in 1943, the domestic drug giant Xinhua Pharmaceutical to continue the promotion of flu drug Philophile. As a result, the domestic OTC market is more prosperous.